VYEPTI is indicated for the preventive treatment of migraine in adults. View patient site
VYEPTI is indicated for the preventive treatment of migraine in adults.
Image of map with location pins

Find a VYEPTI Infusion Network location that works for your patients

The VYEPTI Infusion Network as well as additional sites of infusion are available. Some infusion providers may be able to offer home infusion. Infusion options are subject to your patient's insurance benefit.

DISCOVER INFUSION LOCATIONS
VYEPTI Coverage Finder icon Results shown for illustrative purposes.

Improved access for VYEPTI. Your patients may already qualify

Look up detailed coverage information like prior authorization and step therapy requirements for your patients’ plans. This tool is for informational purposes only. Please consult with each payer to determine actual coverage benefits.

CHECK NOW
VYEPTI copay support card

Copay support for both VYEPTI and the IV administration

The VYEPTI CONNECT® Copay Assistance Program can help eligible patients with commercial insurance:

  • Pay as little as $0 for VYEPTI*
  • Save up to $200 per infusion on their administration out-of-pocket cost*

Offer includes 100 mg and up to 300 mg doses.

ENROLL YOUR PATIENTS NOW

*Your patient’s out-of-pocket cost may vary depending on their dose, insurance coverage, and eligibility. Eligibility criteria and program maximums apply. Copay assistance for IV administration costs is restricted in MA, MN, and RI. This offer is NOT available for patients enrolled in Medicare, Medicaid, or any other government healthcare program. Please see the full Terms and Conditions.

IMPORTANT SAFETY INFORMATION AND INDICATION
CONTRAINDICATIONS

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

For more information, please see the Full Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION AND INDICATION
CONTRAINDICATIONS

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

For more information, please see the Full Prescribing Information and Patient Information.

References:

  1. Diener HC, Antonaci F, Braschinsky M, et al. European Academy of Neurology guideline on the management of medication-overuse headache. Eur J Neurol. 2020;27(7):1102-1116.
  2. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd ed. Cephalalgia. 2018;38(1):1-211.
Site map Terms of Use Privacy Policy Contact us Cookie settings

© 2024 Lundbeck. All rights reserved. VYEPTI and VYEPTI GO are registered trademarks, and VYEPTI CONNECT is a trademark of Lundbeck Seattle BioPharmaceuticals, Inc. EPT-B-101196v4

All trademarks, logos, and brand names are the property of their respective owners. All company, product, and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.

This website is intended for US healthcare professionals only.